Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04408924 · ClinicalTrials.gov registry record · Phase 2
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT04408924 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 44 participants.
The verdict
NCT04408924, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
Interventions
- DRUG Abemaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-01-20 |
| Est. Completion | 2023-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04408924
The ClinicalTrials.gov registry entry for NCT04408924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abemaciclib is the first listed.
NCT04408924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04408924 about?
NCT04408924 is a clinical study titled "Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer". The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.
What is the current status of trial NCT04408924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2021-01-20. Estimated completion is 2023-06-02.
What interventions are being tested in trial NCT04408924?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT04408924?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.